Literature DB >> 2312899

Immunosuppression in patients with metastatic squamous cell carcinoma from the skin.

S M Dinehart1, D Z Chu, A W Maners, S V Pollack.   

Abstract

Sixteen of 70 patients with metastatic squamous cell carcinoma (SCC) from the skin had evidence of clinical immunosuppression. In addition to patients with lymphoproliferative disorders or renal failure, those with cicatricial pemphigoid and those undergoing chronic oral corticosteroid therapy were identified as being at high risk. Host immune surveillance appears to play a major role in determining the metastatic potential of cutaneous SCC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2312899     DOI: 10.1111/j.1524-4725.1990.tb03963.x

Source DB:  PubMed          Journal:  J Dermatol Surg Oncol        ISSN: 0148-0812


  4 in total

1.  [Significance of parotid metastases of squamous cell carcinoma of scalp].

Authors:  A Teymoortash; E S Schultz; J A Werner
Journal:  Hautarzt       Date:  2007-04       Impact factor: 0.751

2.  Histopathological characteristics of metastasizing squamous cell carcinoma of the skin and lips.

Authors:  P J F Quaedvlieg; D H K V Creytens; G G Epping; C J Peutz-Kootstra; F H M Nieman; M R T M Thissen; G A Krekels
Journal:  Histopathology       Date:  2006-09       Impact factor: 5.087

3.  Evaluation of the definitions of "high-risk" cutaneous squamous cell carcinoma using the american joint committee on cancer staging criteria and national comprehensive cancer network guidelines.

Authors:  Melinda B Chu; Jordan B Slutsky; Maulik M Dhandha; Brandon T Beal; Eric S Armbrecht; Ronald J Walker; Mark A Varvares; Scott W Fosko
Journal:  J Skin Cancer       Date:  2014-09-17

4.  Lifestyles, environmental and phenotypic factors associated with lip cancer: a case-control study in southern Spain.

Authors:  E Perea-Milla López; R M Miñarro-Del Moral; C Martínez-García; R Zanetti; S Rosso; S Serrano; J F Aneiros; A Jimenez-Puente; M Redondo
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.